- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Liso-cel is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19,1,2?which is a surface glycoprotein expressed during normal B-cell development and maintained following malignant transformation of B cells.3-5?Liso-cel CAR T cells aim to target and CD-19 expressing cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain.1,2,6-9 The controlled manufacturing process for liso-cel results in a defined composition therapy consisting of CD8+ and CD4+ CAR T cells; however, the clinical significance of defined composition is unknown.1,10
Liso-cel Proposed Mechanism of Action